Oculis Holding AG (NASDAQ:OCS) Sees Large Decrease in Short Interest

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totalling 22,600 shares, a decline of 55.4% from the March 31st total of 50,700 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 52,700 shares, the short-interest ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Several brokerages have recently commented on OCS. Chardan Capital reissued a "buy" rating and issued a $28.00 target price on shares of Oculis in a report on Thursday, April 17th. HC Wainwright increased their target price on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a report on Thursday, April 17th. Finally, Robert W. Baird lifted their price target on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a report on Thursday, March 13th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its position in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after buying an additional 1,800 shares during the period. Bellevue Group AG bought a new position in Oculis during the 4th quarter worth approximately $170,000. Bank of America Corp DE increased its stake in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after purchasing an additional 10,667 shares in the last quarter. XTX Topco Ltd acquired a new stake in Oculis in the fourth quarter worth $225,000. Finally, Citadel Advisors LLC bought a new position in shares of Oculis during the fourth quarter worth $389,000. 22.30% of the stock is currently owned by institutional investors.

Oculis Trading Up 3.6 %

Shares of OCS stock traded up $0.62 on Monday, reaching $17.62. 4,277 shares of the stock were exchanged, compared to its average volume of 43,659. The stock has a 50 day moving average price of $18.45 and a 200 day moving average price of $18.17. The stock has a market cap of $769.32 million, a PE ratio of -9.13 and a beta of 0.19. Oculis has a one year low of $10.79 and a one year high of $23.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02.

Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. Equities research analysts forecast that Oculis will post -2.09 EPS for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.